
Opinion|Videos|September 4, 2024
Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions
Author(s)Jamie L. Koprivnikar, MD, Solly Chedid, MD
Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can we continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients?
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5



































